Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study finds increased risk of liver injury with some TB medications

15.10.2002


A newly recommended treatment for latent tuberculosis (TB) infection can cause liver injury, and therefore needs to be used with great caution and frequent monitoring, according to a UCSF-led, multi-center study.



The research reporting the increased liver injury from the drugs, rifampin and pyrazinamide, was conducted by investigators at UCSF, Boston University, and Emory University and appears in the October 15 issue of the Annals of Internal Medicine.

The study is the first large-scale clinical trial to compare the newly recommended and shorter duration treatment – two months of rifampin and pyrazinamide -- with the standard treatment, six months of isoniazid, to treat patients with latent TB infection.


"We found that patients taking the two-drug treatment had a much higher rate of major liver injury than those who took the standard treatment of isoniazid," said principal investigator Robert M. Jasmer, MD, UCSF assistant professor of medicine, who treats patients in the division of tuberculosis control at San Francisco General Hospital Medical Center (SFGHMC).

Caused by the organism Mycobacterium tuberculosis, TB is a chronic bacterial infection that usually causes disease in the lungs but also attacks other organs. TB is usually dormant (or latent) in the body for years, but around ten percent of latently infected individuals will develop active TB at some time in their lives. It is estimated that 10-15 million people in the U.S. and 2 billion people in the world are infected with TB bacteria. People who have been recently infected or have a condition that increases their chances of developing active TB are recommended to undergo treatment for latent TB infection to prevent them from developing active TB in the future, said Jasmer.

Study findings showed that eight percent of patients taking the rifampin and pyrazinamide regimen developed significant liver injury compared with only one percent of those taking isoniazid. Other side effects and the percentage completing treatment were similar between the two groups.

Previous studies had shown that the two-drug treatment was safe and effective in HIV-infected persons with latent TB infection, so experts recommended this treatment as a new option for all adults in the U.S. in 2000, explained Jasmer. However, the Centers for Disease Control and Prevention (CDC) received reports of eight deaths due to liver failure among patients treated with the two-drug regimen. These deaths led to new recommendations to monitor patients closely every two weeks who are prescribed the rifampin and pyrazinamide treatment.

In the study, known as the SCRIPT (Short-Course Rifampin and Pyrazinamide for TB Infection) Study, 589 patients were enrolled and assigned to treatment with either the rifampin and pyrazinamide regimen or isoniazid. All patients underwent frequent monitoring for side effects and blood tests to detect liver damage. No patients in the study were hospitalized for liver disease, and all had complete resolution of their liver abnormalities after discontinuation of the medications when necessary.

"Our study confirms the new CDC recommendations for frequent monitoring of patients treated with the two-drug regimen so that they are evaluated every two weeks, including testing their blood for markers of liver injury. The vast majority of patients did fine and completed the treatment without major side effects, but laboratory monitoring is essential to detect those with early liver injury and prevent progression to severe toxicity," Jasmer said.

Maureen McInaney | EurekAlert!

More articles from Health and Medicine:

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

nachricht Disrupted fat breakdown in the brain makes mice dumb
19.05.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

Im Focus: Bacteria harness the lotus effect to protect themselves

Biofilms: Researchers find the causes of water-repelling properties

Dental plaque and the viscous brown slime in drainpipes are two familiar examples of bacterial biofilms. Removing such bacterial depositions from surfaces is...

Im Focus: Hydrogen Bonds Directly Detected for the First Time

For the first time, scientists have succeeded in studying the strength of hydrogen bonds in a single molecule using an atomic force microscope. Researchers from the University of Basel’s Swiss Nanoscience Institute network have reported the results in the journal Science Advances.

Hydrogen is the most common element in the universe and is an integral part of almost all organic compounds. Molecules and sections of macromolecules are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

Innovation 4.0: Shaping a humane fourth industrial revolution

17.05.2017 | Event News

Media accreditation opens for historic year at European Health Forum Gastein

16.05.2017 | Event News

 
Latest News

New approach to revolutionize the production of molecular hydrogen

22.05.2017 | Materials Sciences

Scientists enlist engineered protein to battle the MERS virus

22.05.2017 | Life Sciences

Experts explain origins of topographic relief on Earth, Mars and Titan

22.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>